IDEX(US:IEX) ZACKS·2025-10-29 14:31Core Insights - Idex (IEX) reported revenue of $878.7 million for the quarter ended September 2025, reflecting a year-over-year increase of 10.1% and surpassing the Zacks Consensus Estimate by 2.37% [1] - Earnings per share (EPS) for the quarter was $2.03, up from $1.90 in the same quarter last year, exceeding the consensus EPS estimate of $1.93 by 5.18% [1] Financial Performance Metrics - Organic net sales increased by 5% year-over-year, outperforming the estimated 2.4% growth [4] - Net Sales in Fluid & Metering Technologies (FMT) reached $317.1 million, exceeding the average estimate of $305.75 million and representing a 5.4% increase year-over-year [4] - Intersegment sales eliminations were reported at $-1.3 million, better than the estimated $-1.56 million, showing an 18.8% decline compared to the previous year [4] - Net Sales in Fire & Safety/Diversified Products (FSDP) were $181.9 million, below the average estimate of $190.45 million, indicating a 3.2% decrease year-over-year [4] - Health & Science Technologies (HST) net sales were $381 million, surpassing the average estimate of $362.99 million, with a significant year-over-year increase of 22.5% [4] Adjusted EBITDA Performance - Adjusted EBITDA for Fluid & Metering Technologies (FMT) was $106.8 million, slightly above the average estimate of $103.59 million [4] - Corporate adjusted EBITDA was reported at $-21.7 million, better than the estimated $-26.16 million [4] - Adjusted EBITDA for Fire & Safety/Diversified Products (FSDP) was $49.3 million, below the average estimate of $55.1 million [4] - Health & Science Technologies (HST) adjusted EBITDA reached $105.4 million, exceeding the average estimate of $95.53 million [4] Stock Performance - Idex shares have returned +2.6% over the past month, compared to a +3.8% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]